Who is sponsoring NCT02562027?

NCT02562027 is sponsored by Washington University School of Medicine.

What condition does NCT02562027 study?

NCT02562027 studies Carcinoma, Non-Small-Cell-Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer.

Is NCT02562027 still recruiting?

NCT02562027 is currently completed. Last updated 8 April 2021.

Last reviewed 2021-04-08 · How we verify

NCT02562027

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer

Completed NA Last updated 8 April 2021

What this trial tests

NA trial testing European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 in Carcinoma, Non-Small-Cell-Lung in 217 participants. Completed in 1 November 2020.

Timeline

11 September 2015

Primary endpoint
1 November 2020

1 November 2020

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	217
Start date	11 September 2015
Primary completion	1 November 2020
Estimated completion	1 November 2020
Sites	1 location across United States

Drugs / interventions tested

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13
Modified Medical Research Council
EQ-5D
Center for Epidemiological Studies Depression Scale
Medical Outcomes Study Social Support Survey

Conditions studied

Carcinoma, Non-Small-Cell-Lung — all drugs for Carcinoma, Non-Small-Cell-Lung →
Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →
Nonsmall Cell Lung Cancer — all drugs for Nonsmall Cell Lung Cancer →

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with Carcinoma, Non-Small-Cell-Lung or Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A principle objective of the study is to create a validated risk model for treatment selection. This will greatly enhance the ability to counsel patients regarding their specific risks/benefit ratio for surgery or SBRT. This will improve informed decision making on the part of the patient, and remove much of the subjectivity of treatment selection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Harmonized Outcome Measures for Use in Non-Small Cell Lung Cancer Patient Registries and Clinical Practice.
Edelman MJ, Raymond DP, Owen DH, Leavy MB, et al · · 2021 · PMID 34388732 · DOI 10.6004/jnccn.2021.7021

Verify or expand the search:

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02562027 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 8 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02562027.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing